NCT04205838View on ClinicalTrials.gov

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 4, 2020

Primary Completion Date

June 1, 2026

Study Completion Date

June 30, 2027

Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaProgressive DiseaseRecurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory High Grade B-Cell LymphomaRefractory Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRefractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
BIOLOGICAL

Anakinra

Given SC

BIOLOGICAL

Axicabtagene Ciloleucel

Given via infusion

DRUG

Cyclophosphamide

Given via infusion

DRUG

Fludarabine

Given via infusion

DRUG

Fludarabine Phosphate

Given via infusion

Trial Locations (2)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

95817

UC Davis Comprehensive Cancer Center, Davis

All Listed Sponsors
lead

Jonsson Comprehensive Cancer Center

OTHER